Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells

Stem Cells

Volumn 33, Issue 3, 2015, Pages 880-891

  Franquesa, M ^a   Mensah, F K ^a   Huizinga, R ^b   Strini, T ^a   Boon, L ^c   Lombardo, E ^d   Delarosa, O ^d   Laman, J D ^b,e   Grinyo J M ^f   Weimar, W ^a   Betjes, M G H ^a   Baan, C C ^a   Hoogduijn, M J ^a  

^a Internal Medicine   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c BIOCEROS   (Netherlands)

^d TiGenix SAU ^*  (Spain)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

B cell; Immunomodulation; Mesenchymal stem cell; Plasmablast; Regulatory B cell (Breg)

Indexed keywords

CD19 ANTIGEN; CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA;

ADIPOSE DERIVED STEM CELL; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURFACE; CELL SURVIVAL; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCING CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; MESENCHYMAL STEM CELL; PHENOTYPE; PLASMA CELL; PLASMABLAST; PRE B LYMPHOCYTE; PROTEIN EXPRESSION; STEM CELL CULTURE; SUBCUTANEOUS FAT; UPREGULATION; ADIPOSE TISSUE; CELL COMMUNICATION; CELL GROWTH; CYTOLOGY; IMMUNOLOGY; MESENCHYMAL STROMA CELL; PALATINE TONSIL;

ADIPOSE TISSUE; APOPTOSIS; B-LYMPHOCYTES, REGULATORY; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL SURVIVAL; COCULTURE TECHNIQUES; HUMANS; MESENCHYMAL STROMAL CELLS; PALATINE TONSIL; PLASMA CELLS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84923217704     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1881     Document Type: Article

References (55)

1. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
2. Tyden G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325-1329.
3. Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 1490-1495.
4. Pierce SK, Morris JF, Grusby MJ, et al. Antigen-presenting function of B lymphocytes. Immunol Rev 1988; 106: 149-180.
5. Swain SL, Dutton RW,. Consequences of the direct interaction of helper T cells with B cells presenting antigen. Immunol Rev 1987; 99: 263-280.
6. Zeng Q, Ng YH, Singh T, et al. B cells mediate chronic allograft rejection independently of antibody production. J Clin Invest 2014; 124: 1052-1056.
7. Susal C, Opelz G,. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73: 1269-1273.
8. Hodges AM, Lyster H, McDermott A, et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 2012; 93: 650-656.
9. Yanaba K, Bouaziz JD, Matsushita T, et al. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008; 223: 284-299.
10. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
11. Bernardo ME, Fibbe WE,. Mesenchymal stromal cells: Sensors and switchers of inflammation. Cell Stem Cell 2013; 13: 392-402.
12. Duffy MM, Ritter T, Ceredig R, et al. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2: 34.
13. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-4621.
14. Caplan AI, Correa D,. The MSC: An injury drugstore. Cell Stem Cell 2011; 9: 11-15.
15. Melief SM, Schrama E, Brugman MH, et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013; 31: 1980-1991.
16. Engela AU, Hoogduijn MJ, Boer K, et al. Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA. Clin Exp Immunol 2013; 173: 343-354.
17. Spaggiari GM, Capobianco A, Abdelrazik H, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-1333.
18. Spaggiari GM, Abdelrazik H, Becchetti F, et al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009; 113: 6576-6583.
19. Francois M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012; 20: 187-195.
20. Eggenhofer E, Hoogduijn MJ,. Mesenchymal stem cell-educated macrophages. Transplant Res 2012; 1: 12.
21. Franquesa M, Hoogduijn MJ, Bestard O, et al. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol 2012; 3: 212.
22. Asari S, Itakura S, Ferreri K, et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 2009; 37: 604-615.
23. Tabera S, Perez-Simon JA, Diez-Campelo M, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008; 93: 1301-1309.
24. Comoli P, Ginevri F, Maccario R, et al. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 2008; 23: 1196-1202.
25. Guo Y, Chan KH, Lai WH, et al. Human mesenchymal stem cells upregulate CD1dCD5(+) regulatory B cells in experimental autoimmune encephalomyelitis. Neuroimmunomodulation 2013; 20: 294-303.
26. Peng Y, Chen X, Liu Q, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia 2014, 1-11.
27. da Silva Meirelles L, Chagastelles PC, Nardi NB,. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006; 119: 2204-2213.
28. Kim N, Im KI, Lim JY, et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: Experiments and practice. Ann Hematol 2013; 92: 1295-1308.
29. Reinders ME, Rabelink TJ, de Fijter JW,. The role of mesenchymal stromal cells in chronic transplant rejection after solid organ transplantation. Curr Opin Organ Transplant 2013; 18: 44-50.
30. Maumus M, Guerit D, Toupet K, et al. Mesenchymal stem cell-based therapies in regenerative medicine: Applications in rheumatology. Stem Cell Res Ther 2011; 2: 14.
31. Hoogduijn MJ, Roemeling-van Rhijn M, Engela AU, et al. Mesenchymal stem cells induce an inflammatory response after intravenous infusion. Stem Cells Dev 2013; 22: 2825-2835.
32. Hoogduijn MJ, Crop MJ, Peeters AM, et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 2007; 16: 597-604.
33. Crop MJ, Baan CC, Korevaar SS, et al. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009; 87: 896-906.
34. Wiken M, Bjorck P, Axelsson B, et al. Induction of CD43 expression during activation and terminal differentiation of human B cells. Scand J Immunol 1988; 28: 457-464.
35. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005; 5: 1731-1740.
36. Huizinga R, van Rijs W, Bajramovic JJ, et al. Sialylation of Campylobacter jejuni endotoxin promotes dendritic cell-mediated B cell responses through CD14-dependent production of IFN-beta and TNF-alpha. J Immunol 2013; 191: 5636-5645.
37. Hoogduijn MJ, Crop MJ, Peeters AM, et al. Donor-derived mesenchymal stem cells remain present and functional in the transplanted human heart. Am J Transplant 2009; 9: 222-230.
38. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
39. Perez-Andres M, Grosserichter-Wagener C, Teodosio C, et al. The nature of circulating CD27+CD43+ B cells. J Exp Med 2011; 208: 2565-2566.
40. Abdulahad WH, Meijer JM, Kroese FG, et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjogren's syndrome: A double-blind, placebo-controlled study. Arthritis Rheum 2011; 63: 1116-1123.
41. Hirano T, Ishihara K, Hibi M,. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548-2556.
42. Kim J, Lee S, Kim YM, et al. Human follicular dendritic cells promote germinal center B cell survival by providing prostaglandins. Mol Immunol 2013; 55: 418-423.
43. Schweighoffer E, Vanes L, Nys J, et al. The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity 2013; 38: 475-488.
44. Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008; 111: 2755-2764.
45. Nonoyama S, Hollenbaugh D, Aruffo A, et al. B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J Exp Med 1993; 178: 1097-1102.
46. Le Gallou S, Caron G, Delaloy C, et al. IL-2 requirement for human plasma cell generation: Coupling differentiation and proliferation by enhancing MAPK-ERK signaling. J Immunol 2012; 189: 161-173.
47. Krampera M,. Mesenchymal stromal cell 'licensing': A multistep process. Leukemia 2011; 25: 1408-1414.
48. Hoogduijn MJ, Popp F, Verbeek R, et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol 2010; 10: 1496-1500.
49. Blair PA, Norena LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32: 129-140.
50. Kalampokis I, Yoshizaki A, Tedder TF,. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 2013; 15 (suppl 1): S1.
51. Nagasawa T,. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 2006; 6: 107-116.
52. English K, Barry FP, Field-Corbett CP, et al. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007; 110: 91-100.
53. Rafei M, Hsieh J, Fortier S, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008; 112: 4991-4998.
54. Bouaziz JD, Yanaba K, Tedder TF,. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008; 224: 201-214.
55. Eggenhofer E, Benseler V, Kroemer A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3: 297.